
Anergis closes financing round totalling CHF8m
Anergis has closed a financing round totalling CHF8m which was fully subscribed by existing investors and directors and co-led by Sunstone Capital, BioMedInvest and Renaissance PME/Vinci Capital. Anergis will use the proceeds to further advance the clinical development of its lead product AllerT, a vaccine to treat birch pollen allergy,



